MolDX coverage now includes RaDaR ST for monitoring immune-checkpoint inhibitor response in late-stage solid tumors, expanding reimbursement while current ASCO guidance still treats ctDNA as complementary rather than a replacement for standard assessment.
Circulating tumor DNA can detect molecular traces of residual cancer after apparently curative treatment, but proving that acting on an earlier signal improves survival is the harder challenge.
Discover how Natera’s Signatera MRD test may sharpen chemotherapy decisions after colorectal liver surgery and what remains unproven.
Find out how Guardant360 CDx approval could expand liquid biopsy use in HER2-mutant advanced lung cancer treatment selection.
Natera’s Signatera will track molecular response in a refractory melanoma trial. Find out why ctDNA is becoming central to oncology R&D.
Read how SAGA Diagnostics’ AACR 2026 Pathlight data could reshape ctDNA monitoring in metastatic breast and ovarian cancer.
New PREDICT-DNA data suggests ultrasensitive ctDNA monitoring may outperform traditional markers in breast cancer relapse prediction. Read the full analysis.
Adela’s methylome blood test may help detect immunotherapy response earlier in cancer care. Discover what the latest study reveals for clinicians and diagnostics markets.
New I-SPY 2 data suggest personalized ctDNA could transform risk stratification in therapy-resistant early breast cancer. Read the full analysis.
Natera Inc. and Medica Scientia Innovation Research (MEDSIR) have announced a collaborative effort on the MiRaDoR study, a multicenter, phase II clinical trial focused on hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. Sponsored by MEDSIR and funded by F. Hoffmann-La Roche Ltd., the trial uses Natera’s Signatera assay to guide therapy decisions based on circulating tumor